No abstract

Background Ureteral double J stents are widely utilized in urolithiasis. Disturbing stent-related symptoms may occur while the stent is in location. Various medical agents and stent related solutions were examined for this problem. However, the definite drug has still not been found. We aimed to research the effect of propiverine on stent-related symptoms. Method Patients who underwent ureteroscopic stone surgery between June 2020 and May 2022 were included in the study. While the control group was untreated, the treatment group received 45 mg of propiverine daily after 1 week of the operation. Stent-related symptoms were assessed by USSQ at the end of 1st week and 3rd week of surgery. In addition, the intravesical stent parts of all patients were quantitatively measured with a ruler during stent removal at the end of 3 weeks. Results A total of 177 patients were assessed in the study. Eighty-seven of patient were control and 90 patients of them were treatment group. According to USSQ, urinary symptoms scores, body pain scores, general health scores, work performance scores, sexual health scores, additional problem scores, global QoL scores were found decreased in the treatment group (p<0.001 All domains). Intravesical stent length was found positive correlation with urinary symptom score (1st week) of all patients. Conclusion Stent-related symptoms are more likely in patients with longer intravesical stent length. Propiverine successfully relieve stent-related symptoms.

Objective: Ureteral double J stents are widely utilized in urolithiasis. Disturbing stent-related symptoms may occur while the stent is in location. Various medical agents and stent-related solutions were examined for this problem. However, a definite drug has still not been found. We aimed to research the effect of propiverine on stent-related symptoms.Material and Methods: Patients who underwent ureteroscopic stone surgery between June 2020 and May 2022 were included in the study. While the control group was untreated, the treatment group received 45 mg of propiverine daily after 1 week of the operation. Stent-related symptoms were assessed by ureteral stent symptom questionnaire (USSQ) at the end of 1st week and 3rd week of surgery. In addition, the intravesical stent parts of all patients were quantitatively measured with a ruler during stent removal at the end of 3 weeks.Results: A total of 177 patients were assessed in the study. Eighty-seven patients were control and 90 patients of them were treatment group. According to USSQ, urinary symptoms scores, body pain scores, general health scores, work performance scores, sexual health scores, additional problem scores, and global quality of life (QoL) scores were found to decrease in the treatment group (p&lt;0.001 All domains). Intravesical stent length was found positive correlation with the urinary symptom score (1st week) of all patients.Conclusion: Stent-related symptoms are more likely in patients with longer intravesical stent length. Propiverine successfully relieves stent-related symptoms.

Amaç: Prostat kanserinin cerrahi tedavisinde radikal prostatektomiye bazı durumlarda pelvik lenf nodu diseksiyonu (PLND) da eklenmektedir. Hangi hastada PLND yapılması gerektiğini öngören bazı nomogramlar geliştirilmiştir. Çalışmamızda MSKCC, Briganti ve Partin nomogramlarının etkinliğini değerlendirmeyi amaçladık.Gereç ve Yöntemler: Retrospektif olarak çalışmaya Eylül 2020 ile Ekim 2022 tarihleri arasında radikal prostatektomi ve PLND yapılmış prostat kanseri hastaları dahil edildi. Çalışmaya toplamda 94 hasta dahil edildi. Hastaların demografik verileri ve prostat spesifik antijen (PSA), klinik evre, gleason skoru, biyopsi özellikleri gibi verileri kullanılarak Briganti, MSKCC ve Partin nomogramına göre lenf nodu invazyonu oranları hesaplandı.Bulgular: Radikal prostatektomi yapılan 94 hasta çalışmaya dahil edildi. Hastaların 15’inde lenf nodu invazyonu bildirilirken, 79 hastada saptanmadı. Hastaların Briganti, Partin ve MSKCC nomogramlarının eğri altında kalan alan değerleri sırasıyla 0,922, 0,825 ve 0,929 idi. Her 3 nomogramın doğruluk oranı istatistiksel olarak anlamlı şekilde başarılı idi. Sonuç: MSKCC ve Briganti nomogramlarının lenf nodu invazyonunu öngörmedeki duyarlılığı Partine göre biraz daha yüksek bulunmuştur. Ancak Briganti, Partin’e ve MSKCC nomogramları prostat kanseri hastalarında lenf nodu invazyonunu öngörmede güvenle kullanılabilir.

Objective We aimed to determine factors responsible for chronic kidney disease (CKD) following nephrectomy for renal tumours. Methods A retrospective study was undertaken in patients underwent partial or radical nephrectomy due to kidney tumour between January 2015 and June 2020. Patients with eGFR above 60 ml/min/1.73m2 were included in the study. Demographic information, surgical features, eGFR values and some comorbidities of patients were recorded. The patients were evaluated for the development of CKD according to the CKD-EPI equation postoperatively. Results One hundred and sixty-six patients who underwent radical (n = 125) or partial (n = 41) nephrectomy were included to study. According to the logistic regression analysis, radical nephrectomy (adjusted OR 0.139 (95% CI 0.038–0.507), p = 0.003), age (adjusted OR 1.037 (95% CI 1.001–1.074), p = 0.045), preoperative proteinuria (adjusted OR 0.251 (95% CI 0.084–0.750) p = 0.013) and preoperative lower eGFR (adjusted OR 0.943 (95% CI 0.917–0.969) p < 0.001) were determined as independent predictor for development of CKD. Conclusions CKD is an important disease that causes morbidity and mortality. Age, type of surgery and preoperative eGFR and preoperative proteinuria are an independent risk factor for CKD development. Patients should be informed about this problem before surgery.